Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Driving following defibrillator implantation: development and pilot results from a nationwide questionnaire

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Incidence of new onset cancer in patients with a myocardial infarction - a nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Body mass index in young men and risk of inflammatory bowel disease through adult life: A population-based Danish cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Incidence of Immune-mediated Inflammatory Diseases Among Patients With Inflammatory Bowel Diseases in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Abdominal adiposity and cardiometabolic risk factors in children and adolescents: a Mendelian randomization analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Copeptin, a surrogate marker for arginine vasopressin secretion, is positively associated with glucagon

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Lifelines Cohort authors
View graph of relations

BACKGROUND: We characterised the phenotypic consequence of genetic variation at the PCSK9 locus and compared findings with recent trials of pharmacological inhibitors of PCSK9.

METHODS: Published and individual participant level data (300,000+ participants) were combined to construct a weighted PCSK9 gene-centric score (GS). Seventeen randomized placebo controlled PCSK9 inhibitor trials were included, providing data on 79,578 participants. Results were scaled to a one mmol/L lower LDL-C concentration.

RESULTS: The PCSK9 GS (comprising 4 SNPs) associations with plasma lipid and apolipoprotein levels were consistent in direction with treatment effects. The GS odds ratio (OR) for myocardial infarction (MI) was 0.53 (95% CI 0.42; 0.68), compared to a PCSK9 inhibitor effect of 0.90 (95% CI 0.86; 0.93). For ischemic stroke ORs were 0.84 (95% CI 0.57; 1.22) for the GS, compared to 0.85 (95% CI 0.78; 0.93) in the drug trials. ORs with type 2 diabetes mellitus (T2DM) were 1.29 (95% CI 1.11; 1.50) for the GS, as compared to 1.00 (95% CI 0.96; 1.04) for incident T2DM in PCSK9 inhibitor trials. No genetic associations were observed for cancer, heart failure, atrial fibrillation, chronic obstructive pulmonary disease, or Alzheimer's disease - outcomes for which large-scale trial data were unavailable.

CONCLUSIONS: Genetic variation at the PCSK9 locus recapitulates the effects of therapeutic inhibition of PCSK9 on major blood lipid fractions and MI. While indicating an increased risk of T2DM, no other possible safety concerns were shown; although precision was moderate.

Original languageEnglish
Article number240
JournalBMC Cardiovascular Disorders
Volume19
Issue number1
Pages (from-to)240
ISSN1471-2261
DOIs
Publication statusPublished - 29 Oct 2019

ID: 58249073